Novan (NOVN) Priced

Late-stage biotech developing nitric oxide therapies for acne and other skin conditions.

Health Care - Biotechnology

IPO Performance
Latest Trade $5.14 -0.12 (-2.3%)
First Day Return 64.5%
Return from IPO -52.2%
 
Novan IPO News more
  • .
IPO Data
IPO File Date 08/24/2016
Offer Price $11.00
Price Range $11.00 - $13.00
Offer Shares (mm) 4.1
Deal Size ($mm) 45
 
IPO Data
IPO Date 09/20/2016
Offer Price $11.00
Price Range $11.00 - $13.00
Offer Shares (mm) 4.1
Deal Size ($mm) $45
 
Underwriters
more
Business Overview
We are a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using our nitric oxide platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. The two key components of our nitric oxide platform are our proprietary Nitricil technology, which drives the creation of new chemical entities and our topical formulation science, both of which we use to modulate, or “tune,” our product candidates for specific indications. We are using our platform to transform a useful, naturally occurring molecule into a therapeutic pipeline for a host of skin diseases.
We are a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using our nitric oxide platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a...
more
Company Data
Headquarters Durham, NC
Founded 2006
Employees 63
Website www.novan.com
 

Performance vs. IPO Index (IPOUSA)